Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer

You may be eligible if

• Patients must have newly diagnosed prostate cancer with at least one of the following criteria:
• Clinical Stage \> T2
• PSA \> 15 ng/ml
• Biopsy Gleason's sum \> 8
• All patients must have a minimum PSA value of \> 5 ng/ml.
• Patients may not have evidence of distant systemic metastasis.
• Patients may not undergo concurrent hormonal, biologic, or chemotherapy.
• Patients may not have prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-fluorouracil.
• Patients with a history of severe reaction to docetaxel or other drugs formulated with polysorbate 80 will not be eligible.
• Patients may not have an underlying cardiac disease.